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Abstract
Acinetobacter baumannii is a common causative agent of hospital-acquired infections and a leading cause of infection in
burns patients. Carbapenem-resistant A. baumannii is considered a major public-health threat and has been identified by the
World Health Organization as the top priority organism requiring new antimicrobials. The most common mechanism for
carbapenem resistance in A. baumannii is via horizontal acquisition of carbapenemase genes. In this study, we sampled 20
A. baumannii isolates from a patient with extensive burns, and characterized the evolution of carbapenem resistance over a
45 day period via Illumina and Oxford Nanopore sequencing. All isolates were multidrug resistant, carrying two genomic
islands that harboured several antibiotic-resistance genes. Most isolates were genetically identical and represented a single
founder genotype. We identified three novel non-synonymous substitutions associated with meropenem resistance: F136L
and G288S in AdeB (part of the AdeABC efflux pump) associated with an increase in meropenem MIC to 8 µgml 1; and
A515V in FtsI (PBP3, a penicillin-binding protein) associated with a further increase in MIC to 32 µgml 1. Structural
modelling of AdeB and FtsI showed that these mutations affected their drug-binding sites and revealed mechanisms for
meropenem resistance. Notably, one of the adeB mutations arose prior to meropenem therapy but following ciprofloxacin
therapy, suggesting exposure to one drug whose resistance is mediated by the efflux pump can induce collateral resistance
to other drugs to which the bacterium has not yet been exposed.
DATA SUMMARY
1. All raw genome sequences, including Illumina paired-end
short reads and Oxford Nanopore long reads, have been
deposited in the SRA (Sequence Read Archive) under proj-
ect number PRJNA396979. Individual accession numbers
for each strain are provided in Table S1 (available with the
online version of this paper).
2. The annotated genome assembly for strain A2, the refer-
ence genome for the founder genotype, has been submitted
to GenBank under accession number CP024124 (chromo-
some) and number CP024125 (plasmid).
3. Hybrid assemblies for strains A1, A3, A8, A13, A15, A17
and A20 are available in FigShare, https://doi.org/10.4225/
49/5987e14e9b530 (note they were not deposited in Gen-
Bank as they differ from A2 by only 1–4 single nucleotide
polymorphisms as indicated).
INTRODUCTION
Acinetobacter baumannii is a Gram-negative bacterium that
is amongst the six most common causes of multidrug
resistant (MDR) hospital-acquired infections, a group collec-
tively known as ESKAPE pathogens [1]. A. baumannii is a
common causative agent of pneumonia, bacteraemia, uri-
nary tract infections, meningitis and wound infections, espe-
cially in burns patients [2]. A. baumannii is intrinsically
resistant to a broad range of antibiotics; however, over the
last three decades additional acquired resistance has emerged
[3]. Acquired resistance to first-line antibiotics, including
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aminoglycosides, sulfonamides and tetracycline, arose in the
1970s, with most resistance genes residing on the chromo-
some within the resistance island AbaR, acquired indepen-
dently by each A. baumannii lineage [4–9]. During the 1980s
and 1990s, resistance to third-generation cephalosporins and
fluoroquinolones emerged. Upregulation of the chromo-
somal b-lactamase-encoding gene ampC, by ISAba1 or
ISAba125, is the primary mechanism of cephalosporin resis-
tance [10–12]. Fluoroquinolone resistance is primarily medi-
ated through non-synonymous mutations in gyrA and parC,
which interfere with drug binding [13–15]. Carbapenem
resistance is becoming increasingly common, mainly
through the acquisition of carbapenem-hydrolysing oxacilli-
nase genes [3]. Carbapenem resistance has also been associ-
ated with changes in the expression of penicillin-binding
proteins [16] or the AdeABC efflux pump [17, 18], which
can also impact resistance to other drugs, such as fluoroqui-
nolones [19]. The prevalence of carbapenem resistance in
A. baumannii leaves only polymyxins (such as colistin) and
tigecycline available for treatment. Resistance to these drugs
has already been observed [3, 20–22], and in 2017 the World
Health Organization named carbapenem-resistant A. bau-
mannii as the top priority pathogen critically requiring
research and development of new antibiotics [23].
The A. baumannii population primarily responsible for hos-
pital infections in humans largely consists of two globally
distributed clones, GC1 and GC2 [24]. Previous studies
have begun to untangle the evolution of these clones [7, 24],
including the evolution of sub-clones specific to a particular
hospital [25]. However, very few studies have investigated
evolution of A. baumannii within individual patients.
Within-host evolution has been studied in several other
pathogens, including Staphylococcus aureus, Helicobacter
pylori and Burkholderia pseudomallei [26–28]. One study
retrospectively investigated within-host evolution of A. bau-
mannii in patients from a single hospital system, revealing
enrichment for mutations in genes responsible for antibiotic
resistance or immune responses, with the pmrAB genes
(linked to colistin resistance) being the most commonly
mutated [29]. In addition, the regulatory genes adeRS,
responsible for regulating the efflux pump AdeABC, were
also found to be commonly mutated [29]. Another study
compared the genomes of A. baumannii isolated from two
patients pre-treatment (sensitive) and post-treatment (resis-
tant) with polymyxin B, and identified non-synonymous
mutations in the pmrB gene in both cases (one GC1 and
one GC2) [30]. These studies demonstrate mechanisms by
which A. baumannii can adapt rapidly under positive selec-
tion from antimicrobial exposure during therapy with poly-
myxins. However, as both studies only examined pairs of
isolates from each patient, they were unable to examine the
diversification of the pathogen population during prolonged
infection. Furthermore, while we have previously used geno-
mics to unravel the mechanisms of evolution of carbapenem
resistance at the level of an intensive care unit (ICU) [25],
there are no published studies reporting within-host
evolution of carbapenem resistance during an individual
infection.
In this case study, we investigate the evolution of an A. bau-
mannii strain within a single ICU patient, who had exten-
sive burn wounds and developed a prolonged MDR
A. baumannii infection. Treatment of this infection was
complicated by the presence of resistance to most available
drugs at the onset, followed by the emergence of resistance
to meropenem after its therapeutic use. Here, we compared
the genomes of 20 isolates cultured from serial samples of
burn wound sites at nine time points spanning 68 days,
including multiple samples taken at the same time from dif-
ferent body sites. We identified two distinct subpopulations
of meropenem-resistant strains harbouring non-synony-
mous substitutions in adeB and/or ftsI, and used structural
modelling of the encoded proteins to demonstrate that these
mutations can explain the observed loss of meropenem
susceptibility.
METHODS
Bacterial isolates and antimicrobial-susceptibility
profiling
All A. baumannii strains cultured from burn wound sites
during the clinical care of a patient at The Alfred Hospital,
Melbourne, Australia, were included (n=20). Single isolates
from three other patients, who were cared for in the same
IMPACT STATEMENT
Acinetobacter baumannii is a highly drug-resistant patho-
gen that is frequently found within intensive care units
(ICUs) and especially impacts patients with severe burns.
While several studies have examined the global popula-
tion structure of A. baumannii, few have investigated
within-host evolution of A. baumannii in direct response
to antibiotic treatment in a single patient. Here, we ana-
lysed the genetic evolution of A. baumannii isolated from
a patient with severe burns over the course of their stay
in an ICU. The A. baumannii population on this patient was
highly drug resistant, carrying two distinct genomic
islands encoding resistance to several antibiotics, but not
carbapenems. The bacterial population comprised four
distinct subclades, two of which had evolved carbape-
nem resistance over the course of the antibiotic treat-
ment through novel mutations in genes associated with
drug binding. One subclade was also transmitted to
another patient on the ward. While carbapenem resis-
tance is common in A. baumannii, this is generally attrib-
uted to horizontally transferred carbapenemase genes.
These data provide evidence for carbapenem resistance
arising in vivo via non-synonymous substitutions during a
single infection episode, demonstrating carbapenem
resistance can emerge in genetic isolation in response to
exposure to carbapenems and other drugs.
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ward and during the same time as our index patient, were
also included. All bacterial isolates underwent susceptibility
testing using automated methods (VITEK2), with confirma-
tion of meropenem susceptibility and determination of
MICs by Etest as per the manufacturers guidelines
(bioMerieux).
DNA extraction and sequencing
A. baumannii isolates were grown in Luria broth (LB) over-
night at 37 C with shaking. For the extraction of genomic
DNA, we first generated cell lysates using a Bacterial GenE-
lute kit (Sigma) according to the manufacturer’s instruc-
tions for Gram-negative bacteria preparation. Cell lysates
were then cleaned using the Qiagen DNeasy kit according
to the manufacturer’s instructions and DNA was eluted in
nuclease-free water. DNA sequencing libraries were pre-
pared used the Nextera XT protocol, and 100 bp paired-end
sequencing was performed on each sample using the Illu-
mina HiSeq 2500 at the Australian Genome Research Facil-
ity (Melbourne, Australia). Mean insert size for each
genome was 445 bp, with a mean read depth of 121
(Table S1, available in the online Supplementary Material).
All reads were deposited in the SRA (Sequence Read
Archive) under the accession numbers listed in Table S1.
For long-read sequencing, each isolate was grown over-
night at 37 C on LB plates, and then single colonies were
grown overnight at 37 C in LB. Bacterial cell pellets from
3.0ml broth culture were generated by centrifugation at
15 000 g for 5min. DNA was extracted from these pellets
using Agencourt GenFind V2 (Beckman Coulter) with
minor modifications, as described in [31]. No further puri-
fication or size selection is required, as this protocol gener-
ates high molecular weight genomic DNA that is free of
small DNA contamination. Oxford Nanopore Technologies
(ONT) sequencing libraries were prepared without shear-
ing to maximize read length. Adapters were ligated to each
library using the Nanopore 1D ligation sequencing kit
(SQK-LSK108) with the native barcoding expansion kit
(EXP-NBD103) and modifications as described in [31].
The resulting library contained 3530 ng DNA and was
loaded onto an R9.4 flow cell. A MinION MK1b device
(ONT) was used to perform the run using the NC_48
h_Sequencing_Run_FLO-MIN106_SQK-LSK108 protocol,
with 910 pore numbers available. At the completion of the
run, all resulting FAST5 files were transferred to a separate
Linux server, where bases were called using ONT’s Alba-
core command line tool (v1.0.1), using barcode demulti-
plexing and FASTQ output. Adapter sequences were
trimmed from the reads using Porechop (v0.2.0, https://
github.com/rrwick/Porechop), with barcode demultiplex-
ing, and only keeping reads where Albacore and Porechop
agreed on the barcode bin, to prevent cross-barcode con-
tamination. The mean read length was 9148 bp and the
mean read depth per isolate was 59 (Table S1). The
resulting demultiplexed, barcode trimmed reads were
deposited in the SRA (Sequence Read Archive) under the
accession numbers listed in Table S1.
Whole-genome assembly
For the eight isolates for which both long (ONT) and short
(Illumina) reads were generated, hybrid de novo assemblies
were constructed using Unicycler v0.3.1 [32] with default
settings. This resulted in complete assemblies with two cir-
cular replicons (one chromosome and one plasmid) for iso-
lates A1, A2, A8, A13, A15, A17 and A20, and a single
circular replicon (one chromosome) for isolate A3. For the
remaining isolates, for which only Illumina-based short
reads were available, de novo assemblies were generated
using SPAdes v3.6.1 [33] with the kmer sizes parameter set
to 21, 33, 45, 57, 69, 81 and 93. All genome sequences (com-
plete and draft) were annotated with RAST using default set-
tings [34].
Detection of resistance genes and multi-locus
sequence type (MLST)
Raw sequence reads were screened using SRST2 v0.2.0 [35] to
identify (i) antibiotic-resistance genes using the ARG-ANNOT
database [36] and (ii) MLST using the Institut Pasteur
A. baumannii MLST scheme. Assemblies were also screened
for antibiotic-resistance genes using BLAST+ v2.6.0 [37], in
order to determine the genetic context of resistance genes.
Regions containing resistance genes were extracted from the
assemblies and compared with known resistance islands in
A. baumannii using BLAST+, and the comparisons visualized
using ACT [38].
Detection of variation between isolate genomes
Single nucleotide polymorphism (SNP) detection
All isolates were mapped to the completed A2 genome (i.e.
the first strain isolated from the index patient) using Red-
Dog v1beta10.3 (https://github.com/katholt/RedDog) with
default parameters. Briefly, Illumina reads were mapped
using Bowtie2 v2.2.9 [39] using the sensitive-local algorithm
and a maximum insert length of 2000 (set with the x param-
eter). Variant sites (SNPs and indels) were called using
SAMtools v1.3.1 [40]. Isolate A22 was identified as an out-
group, with only 87% coverage of the reference genome
(compared to 99% for all other genomes). This isolate
contained 103 519 SNPs, and was a different sequence type
(ST) to the other strains, so was excluded from further anal-
ysis. Amongst the remaining 22 isolates, a total of 12 SNPs
was identified.
Insertion sequence (IS) variation
ISsaga [41] was used to screen the A2 genome sequence for
all known ISs. ISs detected in the chromosome were
ISAba22, IS26, ISVsa3, ISAba26, IS1326 and ISAba1.
ISMapper [42] was used to screen all Illumina read sets for
evidence of variation in copy number and location of the six
ISs in the other 21 genomes, in comparison to the A2 refer-
ence genome. The depth cut-off was set to 20 (rather
than the default value, 6) to avoid spurious calls in these
deeply sequenced genomes (87–149). Visual inspection of
all ISAba1 hits in all genomes was also undertaken to con-
firm the exact location and orientation of each insertion
site. The ISMapper results were compared to the eight
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finished genome assemblies belonging to the main clone,
and were found to be in complete agreement concerning the
position of all IS insertions.
Pairwise comparison of completed genomes
The eight completed, hybrid genome assemblies were sub-
jected to pairwise base-by-base comparison using the diffseq
function in the EMBOSS package [43]. This analysis con-
firmed all SNPs and indels detected by RedDog, the ISAba1
variation detected by ISMapper, and additionally identified:
the loss of two tRNA genes within A2, the loss of a 52 kbp
phage region in A8, an additional 1 bp intergenic insertion
in A18 and A20, and a 1 bp insertion within Bm3R1 in A2,
relative to all other genomes.
Structural modelling of mutations in AdeB and FtsI
associated with meropenem resistance
Molecular models of AdeB and FtsI were generated using
Modeller [44] and Macro Model (Schrodinger) using the
X-ray crystal structures of homologous membrane pumps
(PDB IDs: 1OY8, 2V50 and 4MT1; sequence identity 45–
60%) and related penicillin-binding proteins (PDB IDs:
3EQU, 3OC2, 3PBQ, 3PBN, 3UE3, 4BPJ and 5ENS;
sequence identity 43–87%), respectively. The models were
then minimized using the MMF94s forcefield in Sybyl-X
2.1.1 (Certara), with the final structures having more than
95% of residues in the allowed region of a Ramachandran
plot. Meropenem was docked into the models using Glide
(Schrodinger), and the position of the ligands in available
crystal structures used to guide placement. The quality of
the models was confirmed with Verify3D (data not shown).
Model structures were examined using Arpeggio [45] and
PyMOL.
The structural consequences of the missense variants were
analysed to account for all the potential effects of the muta-
tions [46]. The effects of the mutations upon the stability of
the proteins was predicted using SDM [47], mCSM-Stability
[48] and DUET [49]. The effect of the mutations upon the
binding affinity for meropenem were predicted using
mCSM-Lig [50–52]. These computational approaches rep-
resent the wild-type residues structural and chemical envi-
ronment of a residue as a graph-based signature in order to
determine the change upon mutation in Gibb’s free energy
of stability or binding.
Presence of mutations in AdeB and FtsI in other A.
baumannii genomes
To determine whether the meropenem-resistance-associ-
ated alleles were present in other A. baumannii genomes,
the protein sequences for these alleles were extracted and
compared to all A. baumannii genomes currently in the
National Center for Biotechnology Information (NCBI)
database as of February 11 2018, using TBLASTN.
RESULTS
During a 3month period in 2013, 20 MDR A. baumannii
isolates (A2–A20, A22) were cultured from swabs collected
from the burn wound sites of a single patient (patient 1)
with extensive burns, who was being treated in the ICU of a
tertiary care hospital in Melbourne, Australia. The A. bau-
mannii were isolated from swabs taken from several differ-
ent sites across the body, sampled at nine time points
(Figs 1b and 2a). Three additional A. baumannii isolates,
cultured from wound swabs from three other patients
admitted to the same ICU ward within a month of patient
1’s stay, were included in the study for comparison. These
were A1 (patient 0, isolated 2 days prior to patient 1’s first
isolate), A21 (patient 2, 9 days after A20) and A23 (patient
3, 59 days after A20).
All 23 A. baumannii isolates were sequenced using the Illu-
mina platform. MLST and SNP analysis indicated that 22 of
the isolates were GC2 (ST 2 according to the Institut Pasteur
7-locus MLST scheme) and formed a single clonal lineage
with a maximum pairwise distance of eight SNPs (Fig. 1a).
A22 was a distinct strain of A. baumannii, separated from
the main clonal lineage by >100 000 SNPs and belonged to a
novel ST. This was the final isolate from patient 1, cultured
3 weeks after the last GC2 isolate, and likely represents sec-
ondary infection with a novel strain.
Variation amongst the 22 clonal isolates
The complete annotated genome sequence of strain A2, the
first isolate cultured from patient 1, was used as a reference
for detailed comparative analyses. A total of 12 SNPs was
detected amongst the 22 clonal GC2 isolates (9/12 non-syn-
onymous, 2/12 synonymous, 1/12 intergenic; Figs 1a and
2c). All isolates except A3 carried identical copies of the 110
kbp plasmid, confirmed by read mapping and assembly. Six
different ISs were present in the chromosome of A2, at a
total of 37 unique sites: ISAba1 (23 sites), IS26 (8 sites),
ISAba22 (3 sites), ISAba26 (1 site), ISVsa3 (1 site) and
IS1326 (1 site). All but one of the IS insertions present in A2
were conserved across all isolates. The exception was a sin-
gle ISAba1 insertion between two genes encoding hypotheti-
cal proteins (coordinates 1 871 431–1 872 182 in A2), which
was absent in A1 but present in all other genomes. Notably
A1 was the first strain isolated, from patient 0, 2 days prior
to Patient 1’s first isolate and, therefore, was considered the
index case.
To facilitate high-resolution analysis of intra-host evolu-
tion, eight of the clonal GC2 isolates from patient 1, and
the index case from patient 0, that displayed distinct geno-
types and AMR phenotypes (strains A1, A2, A3, A5, A8,
A15, A17 and A20) were selected for long-read sequenc-
ing. The combined short- and long-read sequence data
were used to assemble complete genomes for each of these
isolates, which each consisted of a 3.9 Mbp chromosome
and identical copies of a 110 kbp plasmid (with the excep-
tion of A3, which lacked any evidence of plasmid sequence
in short or long reads). Comparison of the completed
genomes to sequences in GenBank via BLAST searches
revealed that the chromosome was most closely related to
A. baumannii GC2 strain XH856 (isolated in 2010 in
China; accession no. CP014541, 99% identity and 95%
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Fig. 1. Population structure of A. baumannii and sample locations. (a) Minimum spanning tree illustrating the population structure of
all isolates, based on all genome variation detected. Circles indicate isolates whose genomes are genetically identical, with circle size
relative to the number of isolates. Circles are coloured to indicate the subclades referred to in the text; grey circles indicate isolates
from other patients. Annotations above connecting lines indicate genome variation detected; non-synonymous SNPs (nsSNPs) in pro-
tein-encoding genes are labelled with the effect on the amino acid sequence; synonymous SNPs (sSNPs) and intergenic SNPs are enu-
merated. Outlines around circles are indicative of meropenem MIC: no outline, MIC<8µgml 1; thin outline, MIC8 µgml 1; thick
outline, MIC32 µgml 1. (b) Body map showing swab locations for samples of each lineage collected from patient 1. Light grey with
glasses, front of patient; dark grey, back of patient. Isolates are numbered in the order the swabs were collected. Circle outlines indi-
cate meropenem resistance, as in (a). L, Left; R, right.
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coverage), and the plasmid was similar to the previously
described plasmid pABTJ2 (accession no. CP004359, 99%
identity and 100% coverage) sequenced from A. bauman-
nii GC2 strain MDR-TJ (isolated in China, year not
reported) [53].
Base-by-base comparison between the eight finished
genomes confirmed the SNP and IS variation data inferred
from short reads, and additionally detected a single base
pair intergenic insertion in A18 and A20, a single base pair
insertion in Bm3R1 (a helix-turn-helix transcriptional
repressor) in A2, the loss of two adjacent tRNA genes
(tRNA-Trp and tRNA-Leu) from A2, and the loss of a 52
kbp phage region in A8 (Figs 1a and 2b).
Nearly half (9/19) of the clonal isolates from patient 1
formed a group of genetically indistinguishable strains
(orange, Fig. 1a) that were isolated from multiple body sites
between days 4 and 28 (Figs 1b and 2a). This dominant
genotype occupied a centroid position in the minimum
spanning tree of all strains from patient 1, suggesting it
likely represents the founder genotype in this patient. The
isolates from the three other ICU patients, which were col-
lected within 1 month before or after patient 1’s infection,
all belonged to the same clone and differed from the
founder genotype by no more than one SNP (Fig. 1a).
The remaining isolates from patient 1 formed four related
subclades, each characterized by a unique set of differences
Fig. 2. Infection timeline for patient 1. (a) Bar chart illustrating meropenem MIC for each isolate, with timeline below showing sample
collection dates (relative to day 0=first isolation from patient 1). Bars are coloured by the genetic subclade, as defined in Fig. 1(a). The
dashed red line shows MIC=8 µgml 1, the EUCAST (European Committee on Antimicrobial Susceptibility Testing) threshold for defining
resistance. (b) Temporal map of mutations identified in each isolate’s genome, coloured by subclade. Orange circles indicate the dates
on which the founder genotype was isolated; all genetic variation in other isolates are shown relative to this founder genotype. The
delta symbol indicates deletion. (c) Timeline of antibiotic treatment. Coloured bars show the length of time patient 1 was treated with
each antibiotic during their stay in the ICU. Antibiotic dosing was as follows: piperacillin/tazobactam, 4.5 g intravenously three times
per day; vancomycin, 1 g intravenously twice per day; ciprofloxacin, 400mg intravenously three times per day; meropenem, 1 g intrave-
nously (increasing to 2 g from day 28) three times per day; colistin, 150mg intravenously twice per day.
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from the founder genotype. Subclade A (n=3, green, Fig. 1)
was characterized by a single SNP and detected only on
swabs taken from the left buttock and right anterior thigh
area, early on in the series (day 4–21). Subclade B (n=2,
blue, Fig. 1) was detected on the left upper back and left
flank in the middle of the series (day 13, day 23). Subclade
C (n=4, purple, Fig. 1) emerged via a stepwise series of
mutations that accumulated later in the series. The initial
SNP was first detected on the left trunk (day 21), and strains
sharing this SNP plus additional mutations were subse-
quently detected on the right trunk (day 28), back (day 34)
and right arm (day 45). The fourth subclade (D) was repre-
sented by a single isolate, A2, cultured from the right medial
thigh on day 0.
To explore the rate of within-host evolution occurring dur-
ing the prolonged infection of patient 1, we calculated for
each isolate: (x) the temporal distance (in days) since the
first detection of the clone in the patient (day 0), and (y) the
genetic distance (in single base pair mutations) from the
founder genotype; and fit a linear regression of y on x
(P=0.0009, R2=0.49). The fitted slope was 0.065, corre-
sponding to a rate of ~1mutation per 15 days (~24muta-
tions per year). As expected, this intra-host mutation rate is
several fold higher than genome-wide substitution rates esti-
mated for A. baumannii spreading between hosts over sev-
eral years (~10 substitutions per year for GC2 and
~5 substitutions per year in GC1 [7, 25]), which are affected
by purifying selection and evolutionary bottlenecks associ-
ated with transmission to new hosts.
Evolution of antibiotic resistance
All A. baumannii isolates cultured from patient 1 were
MDR, displaying resistance to aminoglycosides, fluoroqui-
nolones, trimethoprim/sulfamethoxazole, third- and fourth-
generation cephalosporins (ceftazidime and cefepime), and
carboxypenicillins. Variation was observed in sensitivity to
meropenem (a carbapenem) (see Fig. 2 and detailed below).
All antibiotic-resistance phenotypes besides meropenem
could be explained by acquired resistance genes that were
conserved in all the clonal (GC2) genomes. A variant of the
AbGRI1-1 genomic island was present within the comM
gene [54], encoding resistance to streptomycin (strAB), sul-
fonamides (sul2) and tetracyclines [tetB, tetR(A)]. A variant
of the resistance island AbGRI2-0 was also present [55].
This second resistance island included a partial mercury
resistance operon (mer), and resistance genes for aminogly-
cosides (aph3¢¢Ia, aadA1, aac3-I), sulfonamides (sul1) and
ampicillin (blaTEM-1). In addition to acquired resistance
genes, all isolates also harboured an ISAba1 insertion site
upstream of the intrinsic efflux pump ampC, which is
known to generate resistance to third-generation cephalo-
sporins [10]. The blaOXA-66 gene was also present within the
chromosome. While the encoded Oxa-66 protein can have
intrinsic carbapenemase activity, upregulation via IS ele-
ments or structural changes via non-synonymous mutations
within the protein are required for full carbapenem resis-
tance, neither of which were identified in these genomes
(and all had identical blaOXA-66 gene sequences and pro-
moter regions).
The majority of isolates, including all with the founder
genotype (orange, Figs 1 and 2), displayed meropenem
MIC4 µgml 1 (Table S1). Reduced sensitivity to merope-
nem was first observed in subclade A, which differed from
the founder genotype by a non-synonymous substitution
(G288S) in AdeB (green, Figs 1 and 2). These isolates dis-
played an increased MIC for meropenem (8 µgml 1).
Subclade C isolates also displayed increased meropenem
MICs and carried a different substitution (F136L) in AdeB
(purple, Figs 1 and 2). Isolate A12 differed from the founder
genotype by this SNP alone, and displayed an MIC of 8 µg
ml 1. The later isolates A18, A19 and A20 (days 28, 34 and
45, see Figs 1 and 2) carried the AdeB F136L mutation and
an additional substitution in the penicillin-binding protein
(PBP3) FtsI (A515V), and displayed high-level resistance to
meropenem (MIC32 µgml 1).
The schedule of antimicrobial therapy supplied to patient 1
is shown in Fig. 2(c) and included two courses of merope-
nem. The meropenem-resistant subclade A emerged prior
to the initiation of meropenem treatment and persisted after
its completion; this is potentially because the AdeB efflux
pump can also transfer ciprofloxacin [19, 56] to which the
patient had been exposed prior to first detection of any
AdeB mutations (Fig. 2). The first meropenem-resistant
subclade C isolate, A12, was also collected after the comple-
tion of the first course of meropenem. However, three mer-
openem-sensitive isolates (A14, A15 and A16) were
subsequently recovered, and a second course of meropenem
treatment was initiated. A few days later, a subclade C iso-
late (A18) with the additional ftsI mutation and high-level
meropenem resistance (MIC>32 µgml 1) was recovered,
prompting the introduction of colistin for treatment, with
subsequent resolution of infection.
Structural basis for meropenem resistance
It is striking that both subclades displaying increased MICs
for meropenem carried non-synonymous mutations in the
same protein, AdeB. The AdeABC efflux pump system has
previously been implicated in carbapenem resistance,
through the upregulation of the trans-membrane
protein AdeB [3, 57]. Here, we observed resistance
(MIC8 µg ml 1) in all strains carrying either a G288S
(subclade A, green) or an F136L (subclade C, purple) muta-
tion in AdeB. Structural modelling of AdeB (see Methods)
showed that the residues affected by these two mutations
are located within the intracellular domain of the protein,
which is responsible for the recognition of compounds to be
passed to the outer membrane protein AdeC. Both muta-
tions were within 5Å of the bound meropenem in the
model (Fig. 3a). Both mutations were predicted to mildly
destabilize the local structure [DDGStability
G288S = 0.62±0.15 kcal
mol 1 ( 2.59±0.63 kJ mol 1) and DDGStability
F136L = 0.91±0.14
kcal mol 1 ( 3.81±0.59 kJ mol 1)], opening the drug bind-
ing site and pore, allowing meropenem to be more effec-
tively exported. Neither of these two AdeB mutations were
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Fig. 3. Meropenem bound to AdeB and FtsI. (a) AdeB. The substitutions G288S (subclade A, green sticks) and F136L (subclade C, pur-
ple sticks) are predicted to facilitate binding and export of meropenem, shown here as the orange molecule. (b) FtsI. The substitution
A515V (magenta sticks) is located in close proximity to the binding site for meropenem (orange molecule), and is predicted to increase
the binding affinity and sequestration of the drug. Other variants G523V and H370Y (green sticks), previously observed in carbapenem-
sensitive strains, are predicted to either reduce or have little effect on the binding affinity.
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found in any publicly available A. baumannii genome in the
NCBI database at the time of writing.
High-level resistance (MIC32 µgml 1) was observed only
in the three subclade C strains that carried the FtsI A515V
mutation in addition to AdeB-F136L. Examination of other
A. baumannii genomes in the NCBI database revealed
that eight genomes (CP014291, CP017646, CP017642,
CP014538, CP007535, CP007577, CP006963 and
CP001921) contained the FtsI A515 mutation, without the
corresponding AdeB G288S or AdeB F136L mutations. FtsI
is a class B penicillin-binding protein, associated with cell
division [58]. Two mutations (G523V, H370Y) have been
reported previously in this protein, but they showed no
evidence of contributing to carbapenem resistance [58].
Here, we modelled these mutations and the A515V muta-
tion present in our meropenem-resistant isolates. The
G523V mutation is located approximately 9 Å away from
the meropenem binding site, and was predicted to greatly
destabilize drug binding [ 2.6±0.05 log10 (fold change in
affinity)]. By contrast, H370Y is located quite distal from
the binding site (20 Å) and is predicted to have minimal
effect on the affinity for meropenem [ 0.03±0.08 log10
(fold change in affinity)]. In our data, the mutation A515V
is located close (7 Å) to the drug binding site of the protein
(Fig. 3b). Structural modelling indicated that mutation to
valine would be well tolerated [mildly stabilizing,
DDGStability=0.25 kcal mol
 1 (1.05 kJ mol 1)] and lead to a
significant increase in the binding affinity for meropenem
[0.16±0.04 log10 (fold change in affinity)], explaining the
reduced effectiveness of meropenem against these strains.
DISCUSSION
Here, we showed that the prolonged infection of patient 1
was primarily due to spread of a founding A. baumannii
genotype, most likely acquired from patient 0. Over the
course of antibiotic treatment in patient 1, the A. baumannii
population diversified into three distinct subclades that
were associated with time periods and specific spatial zones
on the body of patient 1, in addition to onward transmission
to two other patients on the ward. During the evolution of
this infection, two meropenem-resistant lineages (MIC
8 µgml 1) emerged via non-synonymous substitutions in
AdeB, with further increase in MIC (32 µgml 1) due to a
non-synonymous substitution in FtsI. The majority of resis-
tance to meropenem and other carbapenems in A. bauman-
nii is due to acquisition of carbapenemases via horizontal
gene transfer; indeed prior to this study, the upregulation of
the AdeABC efflux pump was the only other known mecha-
nism of meropenem resistance in A. baumannii [3, 57, 59,
60]. In this study, we were able to reliably detect indel varia-
tion with long-read sequencing data, and found that indels
were not responsible for the resistance phenotype observed.
However, whilst this long-read data was not crucial to our
analysis, in future studies it may be required to provide bet-
ter resolution.
Previous studies investigating A. baumannii evolution over
short time periods have mostly focused on several patients
within the same hospital system, with only a few samples
taken per patient [29, 61]. These studies indicated that rein-
fection with novel strains often occurred after treatment
[61]. In our patient, only a single isolate taken at the very
end of the series was a completely novel strain, diverged
from the founder genotype by over 100 000 SNPs. The pres-
ence of this novel strain occurred 3 weeks after the core
group of strains and following apparent resolution of the
infection, and may have arisen due to treatment with colis-
tin eradicating the founding strain population. However, at
later time points, only single swabs were taken, and so this
potentially underestimates the diversity of the population
beyond the final course of antibiotic treatment.
These data highlight the therapeutic risks involved with
treating high-burden A. baumannii infections, especially in
the context of prolonged and severe burn wounds. The
phenotype–genotype relationships also highlight the
importance of antibiotic selection pressure being able to
drive resistance not only to the agent being used, but also to
other antibiotics through shared resistance mechanisms.
For example, the study suggests the activity of multidrug
efflux pumps such as AdeABC may be increased through
exposure to quinolones, with subsequent effects on merope-
nem susceptibility. However, the lack of the AdeB mutations
found in this study in other strains indicates that there is
likely a fitness cost to meropenem resistance acquired in
this way, likely more so than meropenem resistance
acquired through the gain of a carbapenemase-resistance
gene or efflux pump upregulation. The various subclades
were identified at several burn wound infection sites, repre-
senting the ease at which bacteria on wounds and the skin
can infect neighbouring sites. The mechanisms of how bac-
teria seed regions of skin are multifactorial, from simply
contacting bedding surfaces and then re-seeding neighbour-
ing areas of skin, to more complex aspects of bacterial pro-
liferation along the skin surface itself or the wound
dressings [62].
The patient history also highlights the importance of cumu-
lative mutations that can ensue after recurrent antibiotic
exposures, culminating in extreme drug resistance, which
supports the practice of taking into account prior antibiotic
exposures when deciding on new empiric treatment of
recurrent burn wound infections. However, while clinicians
are aware of the potential for resistance to emerge, this must
be balanced against the need to choose the narrowest spec-
trum antibiotic they can to achieve optimal therapy with
minimal toxicity, particularly in the context of a non-life-
threatening burn wound infection. In this case, the appear-
ance of meropenem-resistant strains prompted withdrawal
of meropenem therapy. Ten days later, three infecting
strains were then meropenem susceptible, so meropenem
therapy was resumed. However, the apparent reversion to a
susceptible phenotype turned out to be masking the persis-
tence of a resistant subpopulation, which resurged following
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the resumption of meropenem and prompted escalation to
colistin and ultimately resolution of the infection. This
exemplifies the rapid and efficient ability of A. baumannii
to genetically adapt to antibiotic selection pressures, both
upregulating and downregulating resistance in response to
changes in antibiotic-treatment regimens; and highlights
both the need to consider the potential for heterogeneity in
intra-host pathogen populations, and the importance of reg-
ular monitoring of cultures and symptoms for signs of
emerging resistance to guide active antibiotic treatment.
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